Cue Health Inc.: restructuring charge — Cue Health lays off 13% of workforce; FDA rejects priority review for Flu+COVID test

Cue Health Inc.

Workforce reduction of 94 employees (~13% global workforce) as part of new cost reduction plan.
Estimated restructuring charges of $2.1M-$2.8M cash plus $0.1M non-cash stock-based.
FDA on Dec 28, 2023 declined to issue EUA for Flu A/B + COVID-19 molecular test; review not a priority.
FDA cites significant issues, COVID-19 testing landscape, and resource constraints; future EUA submission not precluded.

item 2.05 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Cue Health Inc. announced a restructuring with charges of approximately $2.1 million to $2.8 million (94 employees).

Type: restructuring
Charge: approximately $2.1 million to $2.8 million
Headcount: 94 employees

Exact text from the filing

In connection with the CRP, the Company estimates that it will record an aggregate restructuring charge related to one-time termination benefits in the range of approximately $2.1 million to $2.8 million. The substantial majority of these charges will result in cash expenditures. Cash expenditures in connection with the CRP consist of payments for salary,

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001628945-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.